{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:44Z","timestamp":1793298944047,"version":"4.5.0"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Response Assessment in NeuroOncology (RANO) criteria for response to treatment in glioma make a distinction between enhancing and unenhancing tumors, which reflects assessment of a different biological process underlying the magnetic resonance imaging findings in enhancing and nonenhancing tumors. The recent regulatory approval of tovorafenib has also considered the patients with minor responses (25%-50% decrease) based on the 2D measurement on T2\/FLAIR MR imaging while incorporating other measures of patient benefit. The INDIGO placebo controlled trial led to the regulatory approval of vorasidenib based on the increase in PFS in the active treatment arm, as measured by blinded independent radiology review using the 2D RANO criteria. With that, more insight in the regulatory requirements for approval in low-grade tumors has been obtained, but other issues in assessing outcome in studies on low-grade enhancing tumors remain. These include the added value of volumetric assessment instead of 2D assessments, and assessment of tumor growth rate as an early marker of outcome. This manuscript gives an overview of the current perspective on and challenges of assessing outcome in trials on unenhancing glioma, with both regulatory and clinical perspectives.<\/jats:p>","DOI":"10.1093\/neuonc\/noaf173","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:20:40Z","timestamp":1753172440000},"page":"2514-2523","source":"Crossref","is-referenced-by-count":12,"title":["The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-5127","authenticated-orcid":false,"given":"Martin J","family":"van den Bent","sequence":"first","affiliation":[{"name":"Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-7483","authenticated-orcid":false,"given":"Timothy F","family":"Cloughesy","sequence":"additional","affiliation":[{"name":"Department of Neurology, David Geffen School of Medicine at UCLA , Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2764-6640","authenticated-orcid":false,"given":"Benjamin M","family":"Ellingson","sequence":"additional","affiliation":[{"name":"UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine at UCLA , Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua E","family":"Allen","sequence":"additional","affiliation":[{"name":"Chimerix, Jazz Pharmaceuticals Company , Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-8921","authenticated-orcid":false,"given":"Samuel C","family":"Blackman","sequence":"additional","affiliation":[{"name":"Google Ventures , Mountain View, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W","family":"Kieran","sequence":"additional","affiliation":[{"name":"Day One Biopharmaceuticals , Brisbane, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1756-423X","authenticated-orcid":false,"given":"Joerg C","family":"Tonn","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK) , Partner site Munich ,","place":["Germany"]},{"name":"Department of Neurosurgery, University Hospital of Munich (LMU) , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-5310","authenticated-orcid":false,"given":"Philipp","family":"Karschnia","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Erlangen, Friedrich-Alexander University , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-5022","authenticated-orcid":false,"given":"Maarten","family":"Wijnenga","sequence":"additional","affiliation":[{"name":"Brain Tumor Center at Erasmus MC Cancer Institute , Rotterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-9844","authenticated-orcid":false,"given":"Johan","family":"Pallud","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, IMA-Brain , Paris ,","place":["France"]},{"name":"Service de Neurochirurgie, GHU-Paris Psychiatrie et Neurosciences, Site Sainte Anne , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7003-3017","authenticated-orcid":false,"given":"Robert J","family":"Young","sequence":"additional","affiliation":[{"name":"Neuroradiology Service, Department of Radiology, Memorial Sloan Kettering Cancer , New York City, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7661-797X","authenticated-orcid":false,"given":"Raymond Y","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4347-8149","authenticated-orcid":false,"given":"Ingo K","family":"Mellinghoff","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , New York City, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1454-6461","authenticated-orcid":false,"given":"John","family":"de Groot","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Neurosurgery, University of California , San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4649-327X","authenticated-orcid":false,"given":"Anouk","family":"van der Hoorn","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-7692","authenticated-orcid":false,"given":"Gilbert","family":"Youssef","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School , Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4699-260X","authenticated-orcid":false,"given":"Shawn L","family":"Hervey-Jumper","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California , San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Vogelbaum","sequence":"additional","affiliation":[{"name":"Department of Neuro Oncology, Moffitt Cancer Center , Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Neuro Oncology, Department of Neurological Surgery, University of California San Francisco (UCSF) , San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-7700","authenticated-orcid":false,"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery Department of Neurosurgery, Mass General Brigham, Harvard Medical School , Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"issue":"1","key":"2026012603465139300_CIT0001","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer."},{"issue":"7","key":"2026012603465139300_CIT0002","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol."},{"issue":"3","key":"2026012603465139300_CIT0003","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1212\/01.WNL.0000133398.11870.9A","article-title":"Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression","volume":"63","author":"de Wit","year":"2004","journal-title":"Neurology."},{"issue":"1","key":"2026012603465139300_CIT0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"issue":"18","key":"2026012603465139300_CIT0005","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1200\/JCO.2009.22.4998","article-title":"End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald\u2019s criteria","volume":"27","author":"van den Bent","year":"2009","journal-title":"J Clin Oncol."},{"issue":"2","key":"2026012603465139300_CIT0006","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cncr.23562","article-title":"Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide","volume":"113","author":"Taal","year":"2008","journal-title":"Cancer."},{"issue":"11","key":"2026012603465139300_CIT0007","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol."},{"issue":"4","key":"2026012603465139300_CIT0008","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.20828","article-title":"Succesful treatment of low grade oligodendroglial tumors with a chemotherapy","volume":"103","author":"Biemond-ter Stege","year":"2005","journal-title":"Cancer."},{"issue":"10","key":"2026012603465139300_CIT0009","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/neuonc\/noq055","article-title":"Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas","volume":"12","author":"Peyre","year":"2010","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026012603465139300_CIT0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11060-017-2677-4","article-title":"Long-term impact of temozolomide on 1p\/19q-codeleted low-grade glioma growth kinetics","volume":"136","author":"Izquierdo","year":"2018","journal-title":"J Neurooncol."},{"issue":"7","key":"2026012603465139300_CIT0011","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/2159-8290.CD-19-1030","article-title":"Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes","volume":"10","author":"Clarke","year":"2020","journal-title":"Cancer Discov"},{"issue":"2","key":"2026012603465139300_CIT0012","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-014-1641-9","article-title":"Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics","volume":"121","author":"Taal","year":"2015","journal-title":"J Neurooncol."},{"issue":"6","key":"2026012603465139300_CIT0013","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(20)30064-4","article-title":"Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","volume":"21","author":"Fangusaro","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"2026012603465139300_CIT0014","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S1470-2045(20)30173-X","article-title":"Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","volume":"21","author":"Erker","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"2026012603465139300_CIT0015","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1016\/S1470-2045(20)30166-2","article-title":"Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","volume":"21","author":"Cooney","year":"2020","journal-title":"Lancet Oncol."},{"issue":"8","key":"2026012603465139300_CIT0016","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S1470-2045(22)00222-4","article-title":"Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","volume":"23","author":"Lindsay","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"2026012603465139300_CIT0017","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/neuonc\/noac221","article-title":"Response assessment in pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) Working Group","volume":"25","author":"Hoffman","year":"2023","journal-title":"Neuro Oncol"},{"issue":"33","key":"2026012603465139300_CIT0018","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026012603465139300_CIT0019","author":"FDA","year":"2018"},{"issue":"7","key":"2026012603465139300_CIT0020","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1634\/theoncologist.2017-0152","article-title":"Oncology drug approvals: evaluating endpoints and evidence in an era of breakthrough therapies","volume":"22","author":"Blumenthal","year":"2017","journal-title":"Oncologist."},{"issue":"32","key":"2026012603465139300_CIT0021","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1200\/JCO.23.01865","article-title":"Flashback foreword: bevacizumab and irinotecan in recurrent glioblastoma","volume":"41","author":"Mellinghoff","year":"2023","journal-title":"J Clin Oncol."},{"issue":"8","key":"2026012603465139300_CIT0022","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/neuonc\/now282","article-title":"A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro Oncol"},{"issue":"13","key":"2026012603465139300_CIT0023","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.23.01134","article-title":"ONC201 (Dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma","volume":"42","author":"Arrillaga-Romany","year":"2024","journal-title":"J Clin Oncol."},{"issue":"Supplement_2","key":"2026012603465139300_CIT0024","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1093\/neuonc\/noae031","article-title":"ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma","volume":"26","author":"Arrillaga-Romany","year":"2024","journal-title":"Neuro Oncol."},{"issue":"1","key":"2026012603465139300_CIT0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2023","journal-title":"Nat Med."},{"issue":"6","key":"2026012603465139300_CIT0026","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(11)70057-2","article-title":"Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas","volume":"12","author":"van den Bent","year":"2011","journal-title":"Lancet Oncol."},{"key":"2026012603465139300_CIT0027","author":"FDA","year":"2024"},{"issue":"13","key":"2026012603465139300_CIT0028","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.3390\/cancers15133274","article-title":"Evaluation of RANO criteria for the assessment of tumor progression for lower-grade gliomas","volume":"15","author":"Raman","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"2026012603465139300_CIT0029","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/neuonc\/noab256","article-title":"Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: evidence from a phase I trial of ivosidenib","volume":"24","author":"Ellingson","year":"2022","journal-title":"Neuro Oncol"},{"issue":"5","key":"2026012603465139300_CIT0030","doi-asserted-by":"crossref","first-page":"e1002810","DOI":"10.1371\/journal.pmed.1002810","article-title":"Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: a retrospective observational study","volume":"16","author":"Fathallah-Shaykh","year":"2019","journal-title":"PLoS Med."},{"issue":"3","key":"2026012603465139300_CIT0031","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/neuonc\/noac189","article-title":"Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: an international multi-reader study","volume":"25","author":"Vollmuth","year":"2023","journal-title":"Neuro Oncol"},{"issue":"10","key":"2026012603465139300_CIT0032","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/neuonc\/noae097","article-title":"Digital \u201cflipbooks\u201d for enhanced visual assessment of simple and complex brain tumors","volume":"26","author":"Cho","year":"2024","journal-title":"Neuro Oncol"},{"issue":"4","key":"2026012603465139300_CIT0033","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00234-018-1979-3","article-title":"Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements","volume":"60","author":"D\u2019Arco","year":"2018","journal-title":"Neuroradiology."},{"issue":"4","key":"2026012603465139300_CIT0034","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3174\/ajnr.A8189","article-title":"Comparison of volumetric and 2D measurements and longitudinal trajectories in the response assessment of BRAF V600E-mutant pediatric gliomas in the pacific pediatric neuro-oncology consortium clinical trial","volume":"45","author":"Ramakrishnan","year":"2024","journal-title":"AJNR Am J Neuroradiol."},{"issue":"1","key":"2026012603465139300_CIT0035","first-page":"vdad172","article-title":"Comparison of volumetric and 2D-based response methods in the PNOC-001 pediatric low-grade glioma clinical trial","volume":"6","author":"von Reppert","year":"2024","journal-title":"Neurooncol Adv."},{"issue":"3","key":"2026012603465139300_CIT0036","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.1998.16.3.1234","article-title":"Dimension in defining tumor response","volume":"16","author":"Chappell","year":"1998","journal-title":"J Clin Oncol."},{"issue":"1","key":"2026012603465139300_CIT0037","first-page":"vdae044","article-title":"Diffuse low-grade glioma: what is the optimal linear measure to assess tumor growth","volume":"6","author":"Dos Santos","year":"2024","journal-title":"Neurooncol Adv."},{"issue":"3","key":"2026012603465139300_CIT0038","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00701-018-03783-3","article-title":"Radiology reporting of low-grade glioma growth underestimates tumor expansion","volume":"161","author":"Gui","year":"2019","journal-title":"Acta Neurochir (Wien)."},{"issue":"12","key":"2026012603465139300_CIT0039","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1093\/neuonc\/noaa105","article-title":"Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment","volume":"22","author":"Huang","year":"2020","journal-title":"Neuro Oncol"},{"issue":"2","key":"2026012603465139300_CIT0040","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11060-016-2312-9","article-title":"Intra-rater variability in low-grade glioma segmentation","volume":"131","author":"B\u00f8","year":"2017","journal-title":"J Neurooncol."},{"issue":"7","key":"2026012603465139300_CIT0041","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med."},{"issue":"1","key":"2026012603465139300_CIT0042","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejrad.2008.06.013","article-title":"Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation","volume":"72","author":"Rees","year":"2008","journal-title":"Eur J Radiol."},{"issue":"4","key":"2026012603465139300_CIT0043","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ana.10528","article-title":"Continuous growth of mean tumor diameter in a subset of grade II gliomas","volume":"53","author":"Mandonnet","year":"2003","journal-title":"Ann Neurol."},{"issue":"3","key":"2026012603465139300_CIT0044","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ana.20946","article-title":"Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas","volume":"60","author":"Pallud","year":"2006","journal-title":"Ann Neurol."},{"issue":"8","key":"2026012603465139300_CIT0045","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2007.13.9337","article-title":"Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol."},{"issue":"2","key":"2026012603465139300_CIT0046","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1148\/radiol.2532081623","article-title":"Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient","volume":"253","author":"Brasil","year":"2009","journal-title":"Radiology."},{"issue":"5","key":"2026012603465139300_CIT0047","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ana.21125","article-title":"Dynamic history of low-grade gliomas before and after temozolomide treatment","volume":"61","author":"Ricard","year":"2007","journal-title":"Ann Neurol."},{"issue":"4","key":"2026012603465139300_CIT0048","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/neuonc\/nos069","article-title":"Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas","volume":"14","author":"Pallud","year":"2012","journal-title":"Neuro Oncol"},{"issue":"2","key":"2026012603465139300_CIT0049","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.3171\/2023.11.FOCUS23648","article-title":"Radiographic growth rate as a predictor of aggressiveness of diffuse gliomas without 1p19q codeletion","volume":"56","author":"Leclerc","year":"2024","journal-title":"Neurosurg Focus."},{"issue":"3","key":"2026012603465139300_CIT0050","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ana.21888","article-title":"Pregnancy increases the growth rates of World Health Organization grade II gliomas","volume":"67","author":"Pallud","year":"2010","journal-title":"Ann Neurol."},{"issue":"1","key":"2026012603465139300_CIT0051","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/neuonc\/nox176","article-title":"The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis","volume":"20","author":"Wijnenga","year":"2018","journal-title":"Neuro Oncol"},{"issue":"11","key":"2026012603465139300_CIT0052","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1200\/JCO.21.02929","article-title":"Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma","volume":"41","author":"Hervey-Jumper","year":"2023","journal-title":"J Clin Oncol."},{"issue":"1","key":"2026012603465139300_CIT0053","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-23-1180","article-title":"Tumor volume growth rates and doubling times during active surveillance of IDH-mutant low-grade glioma","volume":"30","author":"Bhatia","year":"2023","journal-title":"Clin Cancer Res."},{"issue":"23","key":"2026012603465139300_CIT0054","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1158\/1078-0432.CCR-23-0585","article-title":"Impact of frontline ivosidenib on volumetric growth patterns in isocitrate dehydrogenase-mutant astrocytic and oligodendroglial tumors","volume":"29","author":"Kamson","year":"2023","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2026012603465139300_CIT0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10143-009-0229-x","article-title":"Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection","volume":"33","author":"Mandonnet","year":"2010","journal-title":"Neurosurg Rev."},{"issue":"4","key":"2026012603465139300_CIT0056","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00179-2019","article-title":"Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis","volume":"5","author":"Ten Berge","year":"2019","journal-title":"ERJ Open Res"},{"key":"2026012603465139300_CIT0057","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.11.24313334","article-title":"Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response","author":"De","year":"2024","journal-title":"medRxiv."},{"issue":"5","key":"2026012603465139300_CIT0058","doi-asserted-by":"crossref","first-page":"95","DOI":"10.21037\/atm.2019.02.14","article-title":"Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancer","volume":"7","author":"Osorio","year":"2019","journal-title":"Ann Transl Med"},{"issue":"1","key":"2026012603465139300_CIT0059","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12885-018-5257-x","article-title":"Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors","volume":"19","author":"Dromain","year":"2019","journal-title":"BMC Cancer"},{"issue":"14","key":"2026012603465139300_CIT0060","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1158\/1078-0432.CCR-17-3662","article-title":"A model of overall survival predicts treatment outcomes with atezolizumab versus chemotherapy in non-small cell lung cancer based on early tumor kinetics","volume":"24","author":"Claret","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2026012603465139300_CIT0061","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/jamainternmed.2020.1097","article-title":"FDA acceptance of surrogate end points for cancer drug approval: 1992-2019","volume":"180","author":"Chen","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"10","key":"2026012603465139300_CIT0062","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41571-023-00794-7","article-title":"Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges","volume":"20","author":"Mountzios","year":"2023","journal-title":"Nat Rev Clin Oncol."},{"key":"2026012603465139300_CIT0063","doi-asserted-by":"publisher","first-page":"113503","DOI":"10.1016\/j.ejc.2023.113503","article-title":"Objective response rate and progression-free survival as surrogates for overall survival treatment effect: a meta-analysis across diverse tumour groups and contemporary therapies","volume":"198","author":"Shahnam","year":"2024","journal-title":"Eur J Cancer."},{"issue":"9","key":"2026012603465139300_CIT0064","first-page":"1188","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials","volume":"17","author":"Ellingson","year":"2015","journal-title":"Neuro Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf173\/63816367\/noaf173.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/10\/2514\/63816367\/noaf173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/10\/2514\/63816367\/noaf173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:47:11Z","timestamp":1769417231000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/27\/10\/2514\/8210166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":64,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,7,19]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf173","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,7,19]]}}}